FDA OKs Invitrogen genetic test for breast cancer
WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Invitrogen Corp's genetic test for determining whether patients with breast cancer are good candidates for treatment with the drug Herceptin.
<p><img src="http://feeds.reuters.com/~a/reuters/scienceNews?i=p7snXY" border="0"></img> (http://feeds.reuters.com/~a/reuters/scienceNews?a=p7snXY)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/scienceNews?i=raLrsJ" border="0"></img> (http://feeds.reuters.com/~f/reuters/scienceNews?a=raLrsJ) <img src="http://feeds.reuters.com/~f/reuters/scienceNews?i=YcRF2j" border="0"></img> (http://feeds.reuters.com/~f/reuters/scienceNews?a=YcRF2j) <img src="http://feeds.reuters.com/~f/reuters/scienceNews?i=ecdIQj" border="0"></img> (http://feeds.reuters.com/~f/reuters/scienceNews?a=ecdIQj)
</div><img src="http://feeds.reuters.com/~r/reuters/scienceNews/~4/329843037" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/scienceNews/~3/329843037/idUSN0819354720080708